NCT03170076Unknown不适用
Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs: Prospective Controlled Clinical Trial
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 1
- 主要终点
- local skin examination
研究概览
简要总结
- Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. It is one of the main causes of chronic liver diseases worldwide .
- According to World Health Organization (WHO), 2011 , Egypt has particularly high rates of Hepatitis C (22%).
- Hepatitis C virus (HCV) is known to induce both hepatic and extra-hepatic manifestations. About 17% of HCV patients present with at least one skin manifestation, which can be directly or indirectly induced by chronic HCV infection .
详细描述
- Skin diseases which are certainly related with chronic HCV infection are mixed cryoglobulinemia, lichen planus , porphyria cutanea tarda, Chronic pruritus and necrolytic acral erythema; conditions that may share a possible association with HCV infection .
- while several immune-mediated inflammatory skin conditions, such as psoriasis, chronic urticaria and vitiligo, have been only rarely reported in the setting of chronic HCV infection .
- Peginterferon based regimen with or without ribavirin were the mainstay of HCV treatment with a cure rate of about 50%, Although these regimens were lengthy, complex, had significant side-effects and high failure rates .
- They also had higher rate of exacerbated dermatologic conditions such as discoid lupus, psoriasis and Lichen planus .
- Recently, Newer all-oral anti viral drugs regimens began to be approved for use in 2014. These regimens, involve one pill daily for 12 weeks, they have achieved sustained virologic response of over 90% and have more tolerable side effect profiles.
- Recently, The European Association for Study of Liver (EASL) 2015, American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) have now recommended that all chronically infected HCV patient should be offered treatment with new oral antiviral drugs .
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with HCV infection eligible for treatment with new (DAADs) and having:
- •A- Normal Complete Blood Count ( hemoglobin not less than 10 gm/dl ). B- Mild to moderate impairment of Liver function test and kidney function test.
- •C- Positive polymerase chain reaction for HCV virus. D- Controlled Blood sugar .
- •Patients > 18 years
排除标准
- •Patients on treatment for skin disease.
- •Pregnancy and lactation.
- •Patients <18 years.
- •Patients not eligible for oral anti hepatitis C drugs.
结局指标
主要结局
local skin examination
时间窗: three months
examination of skin manifestations in patients with hepatitis c under treatment with direct acting anti viral drugs
次要结局
未报告次要终点
研究者
Hagar Maher
Dermatologic resident
Assiut University
相似试验
已完成
不适用
History of Hepatitis C in Volunteer Blood DonorsHepatitis CNCT00001982National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)60
已完成
不适用
Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for VasculitisChronic Hepatitis cVasculitisNCT03693586Hospital General de Mexico1,000
Unknown
不适用
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in AndalusiaChronic Hepatitis CHuman Immunodeficiency Virus (HIV)NCT02511496Maimónides Biomedical Research Institute of Córdoba2,800
招募中
不适用
Immune phenotyping in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks -SODA studyNL-OMON27532AMC32
进行中（未招募）
1 期
A study looking at the immune response in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks.Chronic hepatitis CEUCTR2014-002808-25-NLAcademic Medical Center Amsterdam